{"name":"Immunome, Inc.","slug":"immunome-inc","ticker":"","exchange":"","domain":"immunome.com","description":"Immunome, Inc. is a clinical-stage biotechnology company focused on the discovery and development of novel antibody therapeutics. The company's pipeline includes three drug candidates, with a focus on oncology and immunology.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"Pharma / Biotech","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":6941000,"revenueGrowth":-23.2,"grossMargin":0,"rdSpend":177286000,"netIncome":-212394000,"cash":683188000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2025"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"AL102","genericName":"AL102","slug":"al102","indication":"Other","status":"phase_2"}]}],"pipeline":[{"name":"AL102","genericName":"AL102","slug":"al102","phase":"phase_2","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQYzZ1WkFVendNaW5NUzZvWGdla3MtaENFd2pfWGRSWFZlSGZad21kX1ZQZjdHQ2tZQldrQTBOX0hkcWZ4WnczZlhJQjJPOVlEaWRHSkZTRm5VS0VjSHdhM05rZE50SXJ6SHlWN0ZPLTdwZGw5Z2k1NVYtYXJBOVZjVVlrXzctaTBGYk1Z?oc=5","date":"2026-04-05","type":"pipeline","source":"IndexBox","summary":"Immunome CSO Sells Shares: Transaction Details & Company Snapshot - News and Statistics - IndexBox","headline":"Immunome CSO Sells Shares: Transaction Details & Company Snapshot - News and Statistics","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxQWWVrTFdTTTZkQU4tQURPVkJPWXhHZkJUVmY5X1R1VmJQYjgwaVlYcTNaUnB2WXl0ckZyZGpwVmFmSE14X3JhZ3VXOXJTUUk3ZWNUZXRCNUtfZVg0WXRnT2pBMnhsSzFZNG5rTXcwRi1CVjFtNWpNMl80cFVSTTRZMVdaYjhxUm9UWGRQQ0VORzBiYVFlM0ZXRnN3R0MxMXlKYW9vQjRuWDFodnpVeC1EbEtJeC1EMTI1NXBDN3lrS01GMm_SAcgBQVVfeXFMUHlCS1JkWEc5STZHZkp0M0UwT0tVSmR6d3ZqQmFMM0NpcUFzYjRwaF9TSXNDem0tM3FQMzNiR0NkXzhrakVobnNFOW4zZF9xUDYwVkhTc0pWS0FYaktBbTdlT2pMUzR0TDcwQmtPMk1za1k5YkstX3RIVzZMM185aFBUenVSQjZJbjBYdEtVXzg3aUZYbjN6U3NSeEJtU0lBNGxIXzJsUFQxWnoyOW9TMjJpbXlTQzIxVEdtMFJ5bTRjdGozcHBBR28?oc=5","date":"2026-03-26","type":"pipeline","source":"simplywall.st","summary":"Don't Ignore The Insider Selling In Immunome - simplywall.st","headline":"Don't Ignore The Insider Selling In Immunome","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivwFBVV95cUxNQ1Z1NFVEdDVZVHN1UGs0aTF4R2hLeFFBb0k4YXY2V01DME5NVkk3Szh6am9rTUtYbWRKOFFocUxxYl9ybEZMblBCcjMwM2tKZE5zazJDTWZYUzRFamlaRjhqcVZOVGowX3VOYVdTSXhzV0Q4MHZvT3pqX1Y2VXJxYVJLWWhYdmFwcEhkUEswZmFGb1RuSXdOWkpWZ182bmE0NnQ1SVpMb2IwN3VRRFRfemlJYmQ4OE45UmJHUWIwaw?oc=5","date":"2026-03-21","type":"trial","source":"AD HOC NEWS","summary":"Immunome Inc stock surges on breakthrough oncology data, drawing DACH biotech investor interest - AD HOC NEWS","headline":"Immunome Inc stock surges on breakthrough oncology data, drawing DACH biotech investor interest","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMilwFBVV95cUxQVXZmQVp5S1FKVi03dzg1Z1FVLWM4WXpiRDRJOExQOXJHdFpGdGdQVXpIZWN0V0RUbWRicEQ0dlZFVkt1U3A0ekZseUVvOW9uMFNJVjNrczJaUEVJZUFJNnhWb2lNa1F2RGRTQkV1aS1xZm9jMXdWU3AxYkRvLU5UTXJxMzBHY25GcmlkcUM1NEZnMDNqcjFF?oc=5","date":"2026-03-11","type":"pipeline","source":"Seeking Alpha","summary":"Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM) - Seeking Alpha","headline":"Immunome: Upcoming NDA, Valuation, And Investment Case (NASDAQ:IMNM)","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-03","type":"pipeline","source":"simplywall.st","summary":"How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors - simplywall.st","headline":"How Immunome’s Oncology Pivot and Varegacestat NDA Push Could Impact Immunome (IMNM) Investors","sentiment":"neutral"},{"date":"2026-03-03","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-03","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigAFBVV95cUxPOElkYzhJbHpjbWNGYmJMRHpsYk0xRFhkdjBZYzRrZDhlVWNZVjhobC1MY1libkRZd083STU3Q1JJeFdtQXFaa0VESkE3YXJtRHE1c181eVRTZmQ0eXhBZmdDcDJHajUyRkhYeEVFVmNZQUpabHN1dDY2Um5BaklHeQ?oc=5","date":"2026-03-01","type":"pipeline","source":"Yahoo Finance","summary":"Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development - Yahoo Finance","headline":"Immunome, Inc. (IMNM) Sets Sights on $1B Opportunity amid Pipeline Development","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxPQ1hDTVp2YmkwUnFRZ1QwVlVkdVBxcUdTVHQ3Tms2NURTc091VTREdktfcE55SzBUWmFya212YkRmTUhSc0p3R1l6LWg2SklkdmIzSmVFRDluMUNkUDM2ZFROVm1jV3BHTlNVWTI0cTZDY1hsZ0k0MDNrVk5XS0hTa3ZuSm9Zb2ZUS0hET3BBYTBtbTNBLTlUWXp0ZDdPckxxd0JvTmc3dUNOTTNhTjhYVg?oc=5","date":"2025-12-16","type":"trial","source":"The Pharma Letter","summary":"Immunome up 16% on varegacestat Phase III results in desmoid tumors - The Pharma Letter","headline":"Immunome up 16% on varegacestat Phase III results in desmoid tumors","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwJBVV95cUxNdjhySFF1bXU4VHBZZ0F2UjczMkJiUktDcXFtbS1VMnhmYThGcXhoTkZWTHlRemFxaGU1Y0RMWlY4SlBvSVRidG12em5aUmtQTXNOTmhpOWJEN19DWDZQd2Q5dWlwQ2FoSHhiRTlLMFhBamhwTnlGX2pzWmNaZGMzYW9LaUxQM0JMU3YyQ0JmZjViaFp6azFBOURQWmxNckNEdXgwTk9ZaE9kWHZGYTBIMV81dzEtMlJZeHhCaDlrR3BlMmNkanJtdXJ6dU0tR2NyM0JnX1FsWmQxMWVYeXMwNUVDTVV2ZC1aVW1uQ05BRUc1TWpWeVVLN2Q2MmRrZ1hOeEtWNDV6WQ?oc=5","date":"2025-12-15","type":"trial","source":"Business Wire","summary":"Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors - Business Wire","headline":"Immunome Announces Positive Topline Results from Phase 3 RINGSIDE Trial of Varegacestat in Patients with Desmoid Tumors","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiU0FVX3lxTFAxa2RkbUpXbUZlOFk4NnhfYXpCTWhYcmJMa1Y5ZzYxdFZhYVRwcll0WDcyYXg0SXdiUl9UVVlaREd0NFV2TkFjMDk2aGExQzVIZ2c4?oc=5","date":"2025-04-24","type":"pipeline","source":"Stock Titan","summary":"ADXS Stock Price, News & Analysis | Ayala Pharm - Stock Titan","headline":"ADXS Stock Price, News & Analysis | Ayala Pharm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilgFBVV95cUxOcUE3eG9Sd2ZKUklwZ09XX3JXN3ZHZV9YSVhUb3lrcXdmQ3NraDh1NE5wdkE0YlBzMXZ4RV92NDk3WFFsTm9temRNT3V2eVUyYnNnSEtBbjlqUUVDNTZaZEszeDdfM3ktaTY0VDNDd19pU1hnaS1sWDB3NVVDTW0zR2NZX3Y1bTNqbkIwU0xfaWtFWENZUGc?oc=5","date":"2024-10-30","type":"pipeline","source":"Yahoo Finance","summary":"Immunome Advances with Strategic Asset Acquisition and Agreement - Yahoo Finance","headline":"Immunome Advances with Strategic Asset Acquisition and Agreement","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxOWjZ2S2FkOVptQTBNQkVQRTNjbk5NUk9Ja2t2ZXozWWlJM1BydHJIaXlVNWRlYXNad250clNoZnlBcjNpRWhtank5cTd5ODNLeVlYS01GcUN2NVNsN2hUVkJudlhaVm5TcFB1SUJXcXlab19KTWsxZHFLQzJVOFEwbUtxQ2YxMzhkZ29UVVhDTGZtNm9DM29YSndGZWhUeXpZRTBwSGota201bVR2cVpv?oc=5","date":"2024-02-06","type":"trial","source":"Fierce Biotech","summary":"Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks - Fierce Biotech","headline":"Immunome pays $50M for phase 3 desmoid tumor drug, playing catch-up with SpringWorks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYkFVX3lxTE1TWVc5bUpVM1BpelNialA0V3hCWjYzU2l1SFgxUk5qMU1uVU5lb0MtOG9tc05FTTMxOTdka0RPdUotQ1p4MXRCRkxTXzhyaGc2U2RjT1Zqc3kyV2t3dW5UWmV3?oc=5","date":"2023-10-10","type":"deal","source":"VISTA.Today","summary":"Exton’s Immunome Moves HQ to Seattle Following Merger - VISTA.Today","headline":"Exton’s Immunome Moves HQ to Seattle Following Merger","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"phase_2":1},"enrichmentLevel":2,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":6941000,"revenuePeriod":"2025-12-31","revenueHistory":[{"value":6941000,"period":"2025-12-31"},{"value":9041000,"period":"2024-12-31"},{"value":9041000,"period":"2024-12-31"},{"value":14018000,"period":"2023-12-31"},{"value":14018000,"period":"2023-12-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":177286000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-212394000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":683188000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}